Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354100 · ClinicalTrials.gov registry record · Phase 1
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
A Phase 1 study, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT07354100: Recruiting Phase 1 study, sponsored by University of Chicago.
NCT07354100 is a Phase 1 study that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07354100, a Phase 1 study, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.
Primary Outcome
Change in Bifidobacterium abundance in stool from baseline to week 3.
Interventions
- DRUG Lactulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-12-15 |
| Est. Completion | 2029-04-13 |
| Phase | Phase 1 |
What NCT07354100 shows while recruiting
NCT07354100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Lactulose is the first listed.
NCT07354100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07354100 about?
NCT07354100 is a clinical study titled "Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy". The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.
What is the current status of trial NCT07354100?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2026-12-15. Estimated completion is 2029-04-13.
What interventions are being tested in trial NCT07354100?
The interventions under investigation include: Lactulose (DRUG).
Who is sponsoring clinical trial NCT07354100?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07354100's enrollment target sits among peer trials
55 918th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI